Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 42,400 shares, a decrease of 14.3% from the May 31st total of 49,500 shares. Based on an average trading volume of 60,600 shares, the days-to-cover ratio is currently 0.7 days. Approximately 4.9% of the company’s shares are short sold.

Avenue Therapeutics Price Performance

Shares of Avenue Therapeutics stock traded down $0.03 during trading on Tuesday, hitting $3.37. The stock had a trading volume of 15,581 shares, compared to its average volume of 66,793. The stock has a market cap of $3.17 million, a PE ratio of -0.43 and a beta of -0.19. Avenue Therapeutics has a 12 month low of $3.25 and a 12 month high of $93.75. The firm’s fifty day simple moving average is $4.01 and its 200-day simple moving average is $8.89.

Avenue Therapeutics (NASDAQ:ATXI) last announced its earnings results on Wednesday, May 15th. The company reported ($15.40) earnings per share (EPS) for the quarter.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.